Sandika Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 15-11-2024
- Paid Up Capital ₹ 1.00 M
as on 15-11-2024
- Company Age 37 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.10 M
as on 15-11-2024
- Revenue 13.77%
(FY 2023)
- Profit -107.95%
(FY 2023)
- Ebitda -96.64%
(FY 2023)
- Net Worth -1.13%
(FY 2023)
- Total Assets -0.46%
(FY 2023)
About Sandika Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹0.10 M.
Radha Umre, Sushant Umre, Shivi Chawla, and One other member serve as directors at the Company.
- CIN/LLPIN
U74899DL1987PTC029027
- Company No.
029027
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Aug 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sandika Pharmaceuticals Private Ltd. offer?
Sandika Pharmaceuticals Private Ltd. offers a wide range of products and services, including Personal Care, Oral Care.
Who are the key members and board of directors at Sandika Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Radha Umre  | Director | 01-Apr-1991 | Current |
| Sushant Umre | Director | 03-Jun-2005 | Current |
| Shivi Chawla | Director | 30-Jun-2022 | Current |
| Sanjeev Gulati | Director | 30-Jun-2022 | Current |
Financial Performance of Sandika Pharmaceuticals.
Sandika Pharmaceuticals Private Ltd., for the financial year ended 2023, experienced significant growth in revenue, with a 13.77% increase. The company also saw a substantial fall in profitability, with a 107.95% decrease in profit. The company's net worth dipped by a decrease of 1.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sandika Pharmaceuticals?
In 2023, Sandika Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Maharashtra Creation Date: 07 Jul 2001 | ₹0.10 M | Open |
How Many Employees Work at Sandika Pharmaceuticals?
Unlock and access historical data on people associated with Sandika Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sandika Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sandika Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
